Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 3/20 | 0.67 |
| ▸ | LMNA | P02545 | 2/20 | 0.67 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.67 |
| ▸ | CASP6 | P55212 | 1/20 | 0.62 |
| ▸ | GFER | P55789 | 1/20 | 0.62 |
| ▸ | GPR119 | Q8TDV5 | 7/20 | 0.59 |
| ▸ | NAMPT | P43490 | 1/20 | 0.57 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.55 |
| ▸ | MEN1 | O00255 | 3/20 | 0.55 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.55 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.55 |
| ▸ | HTT | P42858 | 1/20 | 0.54 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.54 |
| ▸ | TSHR | P16473 | 1/20 | 0.54 |
| ▸ | NR1H2 | P55055 | 1/20 | 0.52 |
| ▸ | PDK2 | Q15119 | 1/20 | 0.51 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL7371653 | 0.98 | MAPT (0.65) | MAPTLMNAALDH1A1CASP6GFER | |
| Hydrochloric Acid SCHEMBL4934215 | 0.98 | MAPT (0.65) | MAPTLMNAALDH1A1CASP6GFER | |
| SCHEMBL3194630 | 0.94 | MAPT (0.61) | MAPTLMNAALDH1A1CASP6GFER | |
| SCHEMBL5573222 | 0.92 | MAPT (0.76) | MAPTLMNAALDH1A1GPR119NAMPT | |
| SCHEMBL25827214 | 0.91 | GPR119 (0.56) | MAPTLMNAALDH1A1CASP6GFER | |
| SCHEMBL21946732 | 0.88 | MAPK1 (0.54) | MAPTLMNAALDH1A1CASP6GFER | |
| SCHEMBL10036433 | 0.88 | GPR119 (0.79) | MAPTLMNAALDH1A1GPR119HTT | |
| SCHEMBL23783156 | 0.87 | GPR119 (0.59) | MAPTLMNAALDH1A1CASP6GFER | |
| SCHEMBL8352974 | 0.87 | GPR119 (0.59) | MAPTLMNAALDH1A1CASP6GFER | |
| SCHEMBL13313520 | 0.87 | GPR119 (0.59) | MAPTLMNAALDH1A1CASP6GFER |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1085 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250333385-A1 | DIARYLHYDANTOIN COMPOUNDS | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2025-10-30 | — | — | US | claimed |
| CN-118812446-A | Trifluoromethyl quinazoline derivative and preparation method and application thereof | 贵州省天然产物研究中心 | 2024-10-22 | — | — | CN | claimed |
| CN-115108931-B | Tofenamic acid derivative and preparation and application thereof | 南华大学附属第一医院 | 2024-06-14 | — | — | CN | claimed |
| US-20240132452-A1 | DIARYLHYDANTOIN COMPOUNDS | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2024-04-25 | — | — | US | claimed |
| CN-116640106-B | Phenylpiperazine compound and preparation method and application thereof | 郑州大学 | 2024-03-08 | — | — | CN | claimed |
| CN-116640106-A | Phenylpiperazine compound and preparation method and application thereof | 郑州大学 | 2023-08-25 | — | — | CN | claimed |
| CN-114262321-A | Bistable light-regulated small-molecule protein degradation agent, preparation method and application | 中国药科大学 | 2022-04-01 | — | — | CN | claimed |
| CN-113651799-A | Six-membered non-aromatic ring-containing diaryl pyrimidine HIV-1 reverse transcriptase inhibitor and preparation method and application thereof | 山东大学 | 2021-11-16 | — | — | CN | claimed |
| US-20260137703-A1 | 2-AMINO-PYRIDO[2,3-D]PYRIMIDIN-7(8H)-ONE AND 7-AMINO-1-PYRIMIDO[4,5-D]PYRIMIDIN-2(1 H)-ONE DERIVATIVES AS EGFR INHIBITORS FOR THE TREATMENT OF CANCER | CANCER RESEARCH TECH LIMITED (GB) | 2026-05-21 | — | — | US | disclosed |
| US-20260125382-A1 | COMPOUNDS FOR INHIBITING OR DEGRADING CDK2 AND/OR CDK9 AND MEDICINAL USE THEREOF | KOREA RESEARCH INSTITUTE OF CHEMICAL TECHNOLOGY (KR) | 2026-05-07 | — | — | US | disclosed |
| EP-4717317-A2 | N/O-LINKED DEGRONS AND DEGRONIMERS FOR PROTEIN DEGRADATION | C4 Therapeutics, Inc. (US) | 2026-04-01 | — | — | EP | disclosed |
| US-12583862-B2 | Bifunctional compounds for degrading BTK via ubiquitin proteosome pathway | NURIX THERAPEUTICS, INC. (US) | 2026-03-24 | — | — | US | disclosed |
| US-12570626-B2 | Degraders and degrons for targeted protein degradation | C4 THERAPEUTICS, INC. (US) | 2026-03-10 | — | — | US | disclosed |
| US-12559492-B2 | BRAF degraders | C4 THERAPEUTICS, INC. (US) | 2026-02-24 | — | — | US | disclosed |
| US-5726177-A | HEADACHES; ANXIOLYTIC AGENTS, ANTIDEPRESSANTS, ANALGESICS | PIERRE FABRE MEDICAMENT (FR) | 1998-03-10 | — | — | US | disclosed |
| WO-1998000134-A1 | FIBRINOGEN RECEPTOR ANTAGONISTS | MERCK & CO., INC. (US) | 1998-01-08 | — | — | WO | disclosed |
| WO-1997037975-A1 | CARBOXYLIC ACID DERIVATIVES WITH AN AGGREGATION-INHIBITING ACTION | DR. KARL THOMAE GMBH (DE) | 1997-10-16 | — | — | WO | disclosed |
| EP-0795548-A1 | QUINAZOLINE DERIVATIVES AND USE THEREOF | SUNTORY LIMITED (JP) | 1997-09-17 | — | — | EP | disclosed |
| WO-1997025323-A1 | FIBRINOGEN RECEPTOR ANTAGONISTS | SMITHKLINE BEECHAM CORPORATION (US) | 1997-07-17 | — | — | WO | disclosed |
| US-5556969-A | Benzodiazepine derivatives | MERCK SHARP & DOHME LTD. (GB) | 1996-09-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240132452-A1 | DIARYLHYDANTOIN COMPOUNDS | BPHL, AR, SHBG | MAPT 2915/4885LMNA 3384/4885ALDH1A1 911/4885 |
| US-20260137703-A1 | 2-AMINO-PYRIDO[2,3-D]PYRIMIDIN-7(8H)-ONE AND 7-AMINO-1-PYRIMIDO[4,5-D]PYRIMIDIN-2(1 H)-ONE DERIVATIVES AS EGFR INHIBITORS FOR THE TREATMENT OF CANCER | EGFR, KRAS, O60361 | MAPT 4708/4885LMNA 1830/4885ALDH1A1 999/4885 |
| US-12559492-B2 | BRAF degraders | BRAF, NRAS, HRAS | MAPT 4613/4885LMNA 3247/4885ALDH1A1 2764/4885 |
| US-12570626-B2 | Degraders and degrons for targeted protein degradation | ADRM1, UCHL3, USP30 | MAPT 3677/4885LMNA 4258/4885ALDH1A1 3506/4885 |
| US-20250333385-A1 | DIARYLHYDANTOIN COMPOUNDS | BPHL, AR, SHBG | MAPT 2915/4885LMNA 3384/4885ALDH1A1 911/4885 |
| US-20260125382-A1 | COMPOUNDS FOR INHIBITING OR DEGRADING CDK2 AND/OR CDK9 AND MEDICINAL USE THEREOF | CDK9, CDK20, CDK19 | MAPT 4335/4885LMNA 490/4885ALDH1A1 3278/4885 |
| US-12583862-B2 | Bifunctional compounds for degrading BTK via ubiquitin proteosome pathway | BTK, PSMB2, PSME3 | MAPT 3055/4885LMNA 2427/4885ALDH1A1 4714/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.